

13th Belgian Symposium on the Integration of Molecular Biology Advances into Oncology Clinical Practice

Organizing Committee

Institut Jules Bordet:

A. Awada, N. Kotecki, P. Aftimos, M. Piccart-Gebhart

BSMO:

J. De Grève, P. Vuylsteke, L. Dirix

22 - 23 November 2019
Parker Hotel Brussels,
Bessenveldstraat 15,
Diegem, Belgium

Post-MASCC

Friday 22nd November 2019 Morning

9.00 – 9.05	Introduction – J. Klastersky & C. Fontaine
9.05 – 9.35	Filling the gaps of patient information and comprehension - N. Blijlevens (Netherlands) - TBC
9.35 – 10.05	Cost-effectiveness of newer regimens for the prophylaxis of chemotherapy-induced nausea and vomiting - J. Giuliani (Italy)
10.05 – 10.35	Early and systematic integration of palliative care in oncology care - G. Vanbutsele (Ghent)
10.35 – 10.55	Coffee break
10.55 – 11.25	Emergency management of immune-related toxicities - T. Cooksley (UK)
11.25 – 11.55	Biosimilars in supportive care - E. Foreman (UK)
11.55 – 12.25	Use of G-CSF in elderly patients – J. Klastersky (IJB)
12.25 – 12.30	Conclusions – J. Klastersky & C. Fontaine

13.30 - 14.00		Arrival – coffee and tea
14.00		Welcome – A. Awada (IJB) & S. Rottey (BSMO)
		<u>Precision oncology</u>
14.00 – 15.10	14.00 – 14.20	Rare tumors and histologies : clinical management pathway – C. Jungels (IJB)
	14.20 – 14.40	New advances in agnostic organ therapeutic approaches – M. Lolkema (Rotterdam)
	14.40 – 14.55	Genotype-driven melanoma : what first, targeted therapies or immunotherapy ? – J. Kerger (IJB)
	14.55 – 15.10	Genotype-driven NSCLC : what first, targeted therapies or immunotherapy ? – J. De Grève (UZ Brussel)
		<u>New therapeutic approaches</u>
15.10 - 15.40	15.10 – 15.25	New drugs and formulations in solid tumors : From empirical to molecular approaches – P. Aftimos (IJB)
	15.25 – 15.40	Radiotherapy and immunotherapy : the basis and clinical perspectives – P. Lamblin (Maastricht University)
15.40 - 16.10		Coffee Break
		<u>The dilemma in the first-line setting and beyond</u>
16.10 – 17.10	16.10 – 16.25	Advanced renal cell carcinoma – N. Martinez-Chanza (IJB)
	16.25 – 16.40	Castration sensitive prostate cancer – T. Gil (IJB)
	16.40 – 16.55	Advanced urothelial cancers – P. Barthélémy (Strasbourg)
	16.55 – 17.10	Recurrent head&neck squamous cell carcinoma – TBD
17.10 – 17.25		Pfizer Oncology Award - S. Rottey (UZ Gent)
		<u>Targeted therapies</u>
17.25 – 18.25	17.10 – 17.30	Pancreatic and biliary tract cancers – JL. Van Laethem (Erasme)
	17.30 – 17.50	Advanced esophagogastric cancers – F. Sciafani (IJB)
	17.50 – 18.10	Neuroendocrine tumors – I. Borbath (UCL)

8.00 - 8.30		Arrival – coffee and tea
8.30 - 9.30		<u>Immunotherapy : progress and challenges</u>
	8.30 – 8.50	How to overcome immunotherapy resistance : The new wave of immunotherapy approaches – L. Dirix (GZA)
	8.50 – 9.10	Immunotherapy in specific clinical situation (HIV, auto-immune diseases, elderly, organs transplants, brain metastases,...) – S. Holbrechts (hap)
	9.10 – 9.30	Immunotherapy and predictive biomarkers – V.Siozopoulou (UZA)
9.30 - 10.30		<u>Challenges in solid tumors</u>
	9.30 – 9.45	Clinical research challenges : the role of Oncodistinct network – A. Gonçalves (IPC, Marseille)
	9.45 – 10.00	How to improve the outcome of glioblastomas patients – B. Neyns (UZ Brussel)
	10.00 – 10.15	CNS metastases and the brainstorm program – N. Kotecki (IJB)
	10.15 – 10.30	How to emerge from the “status quo” in colorectal cancers – A. Hendlisz (IJB)
10.30 – 11.00		Coffee Break
11.00 – 11.45		<u>New Multidisciplinary approaches</u>
	11.00 – 11.15	The current landscape of gynecological cancers – J. Vermorken (UZA)
	11.15 – 11.30	Radioisotopic therapies and theranostics in endocrine tumors : An evolving field – I. Karfis (IJB)
	11.30 – 11.45	HIPEC therapy and peritoneal carcinomatosis : indications and limitations – G. Liberale (IJB)
11.45 – 12.00		Molecular management and new strategies of breast cancer – A. Awada (IJB)
12.00 - 12.15		Conclusions